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Abstract
Background: As a leading cause of adult blindness, diabetic retinopathy is a prevalent and profound complication of
diabetes. We have previously reported duration-dependent changes in retinal vascular permeability, apoptosis, and mRNA
expression with diabetes in a rat model system. The aim of this study was to identify retinal proteomic alterations associated
with functional dysregulation of the diabetic retina to better understand diabetic retinopathy pathogenesis and that could
be used as surrogate endpoints in preclinical drug testing studies.
Methodology/Principal Findings: A multi-modal proteomic approach of antibody (Luminex)-, electrophoresis (DIGE)-, and
LC-MS (iTRAQ)-based quantitation methods was used to maximize coverage of the retinal proteome. Transcriptomic
profiling through microarray analysis was included to identify additional targets and assess potential regulation of protein
expression changes at the mRNA level. The proteomic approaches proved complementary, with limited overlap in
proteomic coverage. Alterations in pro-inflammatory, signaling and crystallin family proteins were confirmed by orthogonal
methods in multiple independent animal cohorts. In an independent experiment, insulin replacement therapy normalized
the expression of some proteins (Dbi, Anxa5) while other proteins (Cp, Cryba3, Lgals3, Stat3) were only partially normalized
and Fgf2 and Crybb2 expression remained elevated.
Conclusions/Significance: These results expand the understanding of the changes in retinal protein expression occurring
with diabetes and their responsiveness to normalization of blood glucose through insulin therapy. These proteins, especially
those not normalized by insulin therapy, may also be useful in preclinical drug development studies.
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Introduction
Approximately 97% of patients with Type 1 diabetes develop
some degree of diabetic retinopathy (DR) within 25 years of
diagnosis [1]. Even with improvements in therapies for glycemic
control, DR remains a leading cause of new cases of adult blindness
worldwide [2–4]. With both manifest and subclinical DR, visual
impairment in hue discrimination and contrast sensitivity, delayed
dark adaptation, abnormal visual fields and decreased overall visual
acuity are observed [5–9]. Clinically, the sequence of events in the
pathogenesis of DR and the nature of interplay of vascular
dysfunction, dysregulated metabolism, and neuronal damage
remain to be determined [10].
Research using rat models of diabetes have contributed to the
concept of diabetic retinopathy as a progressive neurovascular
complication that includes vascular, inflammatory, and neuronal
components [11–14]. In previous reports, we have identified
retinal transcriptomic changes with diabetes associated with
vascular dysfunction, a pro-inflammatory state, and neuronal
compromise [12,14,15].
Reports detailing the retinal proteome in human subjects with
DR or animals models of DR are limited. The difficulty in
obtaining human retina samples has led to studies using vitreal
protein collected from subjects. These studies have provided novel
and important insights including the potential role of carbonic
anhydrase in vascular leakage [16,17]. Other human studies of
vitreous have identified additional targets for investigation
including Complement proteins [18], acute phase proteins [19],
Apolipoprotein A1 [20], and interphotoreceptor retinoid-binding
protein [21]. These studies provide valuable new insights but do
not directly address proteomic changes occurring in the retina.
Availability of human post-mortem retinal samples is limited, but
animal model systems offer the potential to examine diabetes-
induced alterations in retinal protein expression. There are a
relatively limited number of reports examining the retinal
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16271proteome with diabetes. Studies using rat [22–24] and mouse
models [25] have identified a number of novel changes in the
diabetic retina but have generally relied on a single proteomic
approach and have not confirmed discovery findings with
independent techniques in multiple animal experiments.
The present study used a multi-modal proteomic discovery
approach (Figure 1). A number of quantitative proteomic
techniques are currently in use, but no single method provides
comprehensive proteomic coverage and previous reports have
suggested that individual methods preferentially detect proteins
with certain biophysical characteristics [26]. Therefore, this study
used Luminex [27], DIGE [28], and iTRAQ [29] methods. These
three approaches use distinct methods of both protein separation
(Luminex – antibody affinity; DIGE - electrophoretic separation of
intact proteins; iTRAQ – liquid chromatography of peptides) and
quantitation (Luminex – antibody binding; DIGE – imaging of
fluorescently-labeled intact proteins, iTRAQ – MS/MS quantita-
tion of tagged peptides). These results were combined with
transcriptomic data to identify targets for confirmation in
independent animals and after insulin therapy. Changes in retinal
protein and mRNA expression were examined in the streptozot-
ocin-induced Sprague Dawley rat after three months of diabetes.
Previously we have determined that in this model, early
pathological features of DR, including retinal apoptosis and
vascular permeability, are evident at this, but not earlier, time
points [14]. We therefore selected this timepoint as a duration of
diabetes with clinically-relevant pathophysiological characteristics.
Results
Animal Data
Five independent experiments were performed in this study.
The rat biometric data are summarized in Table 1. At harvest (3
months after STZ or vehicle injection) diabetic rats were
hyperglycemic and underweight in comparison to controls as with
previous assessments [12,14]. Glycosylated hemoglobin levels (%
HbA1c) were significantly increased in diabetic animals compared
to controls as well (Experiments 3 & 4). In Experiment 5,
treatment with subcutaneous slow-release insulin pellets for the
second 1.5 months of the 3 month diabetic period significantly
reduced blood glucose levels compared to untreated diabetics
(p,0.001, SNK post-hoc) to levels not significantly different from
controls. Diabetic animals receiving insulin weighed more than
untreated diabetic animals but were still significantly lower in
weight than controls (p,0.001, SNK post-hoc, in both compar-
isons). Insulin treatment also reduced HbA1c levels significantly
compared to untreated diabetic animals but HbA1c levels
remained slightly elevated compared to controls (p,0.001, SNK
post-hoc, in both comparisons).
Luminex
Of the 59 growth factors, cytokines, and signaling molecules
examined in the directed Luminex analysis 46 were observed at
detectable levels (Table 2). Four proteins had significant
differences in abundance between diabetic and control groups (t-
test, two-tailed). Fgf2, haptoglobin, and IL-4 levels were elevated
in diabetic animals, while IL-17 levels were significantly decreased
in diabetic levels. Due to the small magnitude of differences for IL-
4 and IL-17, confirmation analysis was focused on Fgf2 and
haptoglobin. The full Luminex data set is available in Table S1.
DIGE
Labeled retinal proteins from control and diabetic rats were
separated by isoelectric point and molecular weight, producing
consistentspot patternsonanalytical andpreparativegels (Figure 2).
Figure 1. Study design. To provide the widest proteomic coverage possible, three different proteomic discovery approaches (iTRAQ, DIGE, and
Luminex) were used. In addition to proteomic discovery analyses, whole-genome transcriptomic analysis was performed. Following data integration,
mRNA and protein validation studies were performed in independent animal sets. Lastly, confirmed changes were examined for responsiveness to
insulin therapy.
doi:10.1371/journal.pone.0016271.g001
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Experiment Condition n Weight (g) Blood Glucose (mg/dL) HbA1c (%) Analyses
1 Control 8 529612 7264 Not Assayed Luminex, DIGE,
iTRAQ
Diabetic 8 261617* 333617* Not Assayed
2 Control 5 610657 7869 Not Assayed Microarray
Diabetic 5 311639* 409639* Not Assayed
3 Control 9 591618 94643 . 4 60.1 Immunoblot, qPCR
Diabetic 9 316617* 371617* 7.960.5*
4 Control 10 551671 127620 3.460.4 Immunoblot
Diabetic 10 280657* 487671* 7.661.9*
5 Control 8 575653# 132611 3.560.1# Immunoblot, qPCR
Diabetic 8 311640*# 496641* 9.060.8*#
Diabetic+Insulin 8 407644* 117672* 5.361.4*
Data are presented as mean 6 standard deviation.
*p,0.001 vs. Control;
#p,0.001 vs. Diabetic+Insulin.
doi:10.1371/journal.pone.0016271.t001
Table 2. Luminex Results.
Protein Diabetic/Control p value Protein Diabetic/Control p value
Apo A1 1.2 IL-6 0.9
CRP 1.2 IL-7 1.0
EGF 0.9 IP-10 1.1
Endothelin-1 1.1 LIF 0.9
Eotaxin 1.5 Lymphotactin 1.2
Factor VII 1.1 MCP-3 1.1
FGF-9 1.1 M-CSF 1.1
FGF-2 2.0 *** MIP-1alpha 1.4
Fibrinogen 1.0 MIP-1beta 1.0
GCP-2 0.9 MIP-1gamma 1.0
GM-CSF 1.0 MIP-2 0.9
Haptoglobin 1.5 ** MIP-3beta 1.0
IFN-gamma 1.3 Myoglobin 1.1
IgA 1.1 OSM 1.0
IL-10 1.1 RANTES 1.1
IL-12p70 1.0 SAP 1.1
IL-17 0.8 * SCF 1.0
IL-18 1.0 SGOT 1.1
IL-1alpha 1.1 TIMP-1 1.0
IL-1beta 1.0 Tissue Factor 1.1
IL-2 1.0 TNF-alpha 0.9
IL-3 1.1 TPO 0.9
IL-4 1.2 * VEGF 1.0
46 of the 59 proteins in the assay were detected within the range of the standards. Four proteins demonstrated significant differences between control and diabetic
groups.
*p,0.05,
**p,0.01,
***p,0.001, two-tailed t-test, n=8/group.
doi:10.1371/journal.pone.0016271.t002
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n=6–8/group for differential expression analyses. After subtracting
local background and normalizing to Cy-2 signals for inter-gel
comparisons, 48 protein spots were determined to be significantly
different between control and diabetic rats ($1.1-fold change, two-
tailed t-test, p,0.05). Differential protein expression represented
both inductions and reductions with diabetes, ranging from
approximately 2200% to 500% of control levels.
368 protein spots, including all spots matched to those with
significant differential expressionand a selection of other spots,were
picked for MS-MS/MS protein identification. 288 proteins spots
were confidently identified, including 32 of the 48 protein spots with
significant differential expression and a fold change $1.1 or #0.9
(Table 3). Sixteen significantly up-regulated and 16 down-regulated
proteins were confidently identified and included several crystallin
isoforms, signaling molecules and metabolic enzymes. Aldolase,
Cryaa, Crybb2, and Hspa1b were chosen for confirmation analysis.
The observation of altered retinal crystallin expression with diabetes
confirms our previous findings [23] in this model and we therefore
expanded our confirmation analysis to include crystallin isoforms
Cryab and Cryba2. The full DIGE data set is available in Table S2.
iTRAQ
In the quantitative LC-MS/MS analysis with isobaric tags, 455
proteins were confidently detected with at least two peptides
identified with greater than the 95% confidence required for
accurate quantitation. A total of 27 proteins were significantly
regulated (t-test, two tailed) with a fold change filter of $1.1 or
#0.9. Differential expression was distributed equally between
down- (14 proteins) and up- (13 proteins) regulated species
(Table 4). Proteins exhibiting expression differences included
signaling, cytoskeletal, and neuronal proteins. An example of
iTRAQ data is provided in Figure 3 with a representative MS/MS
spectrum and quantitation data for a confidently identified peptide
component of Anxa5. Anxa5, Hspa1b, Marcks, Dbi, Gnat1, and
Rcn were chosen for confirmational analysis. The finding of
reduced VAMP2 protein expression after three months of
hyperglycemia agrees with our previous observations in this model
[13]. The full iTRAQ data set is available in Table S3.
Transcriptomic
To complement the proteomic analyses, transcriptomic analysis
was performed. In the whole-genome transcript analysis of samples
from Experiment 2, 11,874 of 22,517 probes on the microarrays
met criteria for detection in at least one of the two groups. Within
groups, highly consistent gene expression was observed. Examining
pair-wise correlationsbetweenindividual animals acrossalldetected
probes, the r
2 was .0.989 for all control comparisons and .0.982
for all diabetic comparisons. A total of 1274 changes (p,0.05, .1.2
fold magnitude change) were observed, with 583 up-regulated and
691 down-regulated probes as illustrated by a heatmap schematic
(horizontal brackets) (Figure S1). The full listing of differentially
expressed mRNAs is available in Table S4. As expected, informatic
analysis of gene expression pattern similarity clustered all control
animals together and all diabetic animals together (vertical
brackets). Transcriptomic data were validated by detection of
significant changes in 12 of the 14 previously described transcrip-
tomic markers of retinopathy [12], with the only two exceptions
showing consistent ratios to previous studies but failing to reach
statistical significance. Additionally, a number of acute phase targets
identified previously [30] were also identified in this analysis. To
extend these transcriptomic findings, Stat3, Cp, and Lgals3 were
chosen for confirmation at the level of protein expression. The full
complement of microarray data is available through the Gene
Expression Omnibus under accession# GSE24423.
Informatics
Complementarity of the multi-modal proteomic approach used
here was assessed by comparing identities and biophysical
properties of unique species detected/identified by technology.
Overlap in proteomic coverage was limited (Figure 4A), with no
commonality between DIGE and Luminex, and only one species
(Got1) detected by both iTRAQ and Luminex. Non-directed
approaches demonstrated more overlap, with 110 unique protein
products identified by both DIGE (154 proteins total) and
iTRAQ (439 proteins total). As expected, the majority (.80%) of
species detected/identified by proteomic approaches were also
detected at the transcriptomic level by high-density microarray
analysis (Figure 4A). Commonality between methods at the level
of differential expression was much more limited, with little
overlap between proteomic methods. Only Hspa1b and Lap3,
which were determined to be up-regulated with diabetes by both
DIGE and iTRAQ, were observed by multiple methods
(Figure 4B). Importantly, this limited overlap was not due to a
protein being observed as differentially expressed by one
proteomic method and unchanged by another. Rather, the
differences in proteins identified as differentially expressed were
largely observed by only one method. Comparison of differen-
tially-expressed species identified by proteomic and transcrip-
tomic analyses demonstrated that few (,10%) changes in protein
Figure 2. Examples of differentially expressed proteins iden-
tified by DIGE. Retinal protein isolated from three-month diabetic and
age-matched control rats was separated and quantitated by DIGE
analysis with identification by MS/MS. Two examples of confidently
identified, differentially regulated protein spots are shown. The upper
panels depict spot location and signal intensity, while the lower panels
depict three-dimensional representations of the densitometric spot
volumes used for quantitation. Both Cryaa and Crybb2 crystallin
isoforms were significantly increased in expression (by 491% and 305%,
respectively) in diabetic rats compared to controls. * p,0.05, two-tailed
t-test, n=8/group.
doi:10.1371/journal.pone.0016271.g002
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comparative analysis of the different methods is illuminating it
should be noted that the same number of samples were not used
in each analysis due to differences in the techniques resulting in
slightly differing levels of statistical power.
Potential reasons for the differential coverage of the proteome
between proteomic methods are inherent differences in the
techniques that may select for proteins with certain biophysical
properties (though this is less likely with the Luminex approach in
which the analytes are selected). The general biophysical
properties of proteins identified by each proteomic approach were
similarly distributed across molecular weight and GRAVY score
ranges (Figure S2). In each method, detection/identification rates
were highest in the 10–40 kDa range and for hydrophilic proteins
(indicated by negative GRAVY scores), although proteins
identified by iTRAQ tended to be more hydrophilic while DIGE
provided slightly more coverage of hydrophobic proteins.
Confirmation of discovery findings in independent
experiments
Toconfirmdiscoveryfindings,immunoblot confirmationanalysis
was performed using two sets of animals, independent from the
discovery experiments (Experiments 3 & 4, Table 1) on selected
targets generated from each discovery method. To complement the
protein confirmations, mRNA target expression was also examined
in the Experiment 3 samples. Targeted protein and mRNA
quantitation exhibited high confirmation rates of statistically
significant differential expression in both validation experiments.
Two patterns of expression were evident with one set of proteins
regulated at both the transcript and protein levels (Cp, Lgals3, Fgf2,
and Stat3) (Figure 5) and another set with altered protein expression
but no significant changes in transcript expression (Cryaa, Cryab,
Cryba3, Crybb2, Dbi, and Anxa5) (Figure 6). In all cases the
significant differences in protein or mRNA agreed with the
discovery findings. Targets from each of the discovery findings
Table 3. Significant protein differences identified by DIGE analysis.
Protein AC# Protein Name Symbol Diabetic/Control p-value
19526477 Crystallin; alpha A Cryaa 4.91 *
19526477 Crystallin; alpha A Cryaa 4.35 *
3891675 Crystallin, beta B2 Crybb2 3.05 *
66730521 Glutathione S-transferase 8 Gsta2 1.47 **
13928850 3-phosphoglycerate dehydrogenase Phgdg 1.30 **
16758348 Peroxiredoxin 6 Prdx6 1.29 *
1373230 Adenosine kinase Adk 1.26 **
56090564 Galactose mutarotase Galm 1.26 *
52345435 Adenosine kinase Adk 1.19 *
81884653 Aminoacylase-1A Acy1 1.16 *
47059179 Heat shock 70 kD protein 1B Hspa1b 1.16 *
347019 DnaK-type molecular chaperone hsp72 Hsp72 1.14 **
40254595 Dihydropyrimidinase-like 2 Dpysl2 1.13 *
51092266 Hypoxanthine guanine phosphoribosyl transferase Hprt1 1.12 *
13242237 Heat shock protein 8 Hspa8 1.10 *
58865398 Leucine aminopeptidase 3 Lap3 1.10 *
13096481 S- Adenosylhomocysteine Hydrolase Ahcy 0.90 *
40254595 Dihydropyrimidinase-like 2 Dpysl2 0.89 *
25742763 Heat shock 70 kD protein 5 Hspa5 0.89 *
8393706 Lactate dehydrogenase A Ldha 0.88 *
16757994 Pyruvate kinase Pkm2 0.88 *
114326546 Phosphoglycerate mutase 1 Pgam1 0.88 *
8393706 Lactate dehydrogenase A Ldha 0.86 *
202837 Aldolase A Aldoa 0.85 **
203078 Nucleolar protein B23.2 Npm1 0.85 *
114326546 Phosphoglycerate mutase 1 Pgam1 0.85 *
6680045 Guanine nucleotide-binding protein; beta-1 subunit Gnao1 0.84 *
19924089 Nucleoside diphosphate kinase A Nme1 0.83 ***
8393706 Lactate dehydrogenase A Ldha 0.83 *
56090293 Pyruvate dehydrogenase beta Pdhb 0.83 *
19526477 Crystallin; alpha A Cryaa 0.78 *
204444 Guanine nucleotide-binding protein alpha subunit Gnb1 0.74 *
Thirty-two protein spots with significant differences (t-test, *p,0.05, **p,0.01, ***p,0.001) between diabetic and control groups were identified with high confidence
in the mass spectrometry analysis.
doi:10.1371/journal.pone.0016271.t003
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microarray - Cp, Lgals3, Fgf2, and Stat3) were confirmed by
orthogonal methods suggesting the quantitative validity of the
discovery methods and reproducibility of the animal model.
Confirmation experiments of haptoglobin, Hspa1b, Marcks,
Gnat1, and Rcn did not reveal specific protein detection at the
appropriate molecular weight with the antibodies tested. Aldolase
was specifically detected but protein expression levels were
unchanged (data not shown).
Effect of insulin treatment
To test the effect of restoration of normoglycemia by exogenous
insulin on retinal protein and mRNA expression, rats received
continuous insulin administration by implantation of subcutaneous
pellets for the last 1.5 months of the 3 month diabetic period
(Experiment 5). Expression of the 10 proteins confirmed in the
previous animal experiments was quantified by immunoblotting. A
number of different patterns in protein expression were observed,
with some changes not normalized by insulin, others partially
normalized and some completely returned to control levels. Fgf2
protein and mRNA expression were not normalized by insulin
treatment, with levels remaining significantly elevated compared to
controls (Figure 7). Insulin treatment partially normalized the protein
expression of Cp, Lgals3, and Stat3 with the insulin-treated group no
longer significantly elevated from control but also not significantly
lower than the diabetic group (Figure 7). The diabetes-induced
increases in Dbi and Anxa5 protein and mRNA expression were
completely normalized (Figure 8). Crystallin isoform expression
demonstrated a variety of patterns. Crybb2 protein expression was
not normalized by insulin treatment, while Cryba3 protein expression
was partially normalized. Unexpectedly, despite the confirmation of
Cryaa and Cryab in previous experiments, no changes in protein
expression with diabetes were observed in this experiment.
Discussion
The results of the combined proteomic, transcriptomic, and
confirmation experiments both validate previously reported
changes in retinal protein expression with diabetes and identify
novel changes. These findings have implications for both our
understanding of the pathogenesis of DR and as preclinical drug
development biomarkers. Additionally, the combination of
discovery approaches used provides comparative insight into
commonly used quantitative proteomic techniques.
Biomarker development
The proteomic profiling and confirmation experiments detailed
in this report could be used as the first stages towards developing a
Table 4. Significant protein differences identified by iTRAQ analysis.
Protein AC# Protein Name Symbol Diabetic/Control p-value
55977739 Heat shock 70 kDa protein 1/2 Hspa1b 2.02 *
157830218 Annexin V Anxa5 1.94 *
78103212 Thymosin beta-4 Tmsb4x 1.56 *
576438 Glutathione transferase A3 Gsta3 1.53 **
266495 Myristoylated alanine-rich C-kinase substrate Marcks 1.51 *
54261671 Diazepam binding inhibitor Db1 1.41 *
76779404 Tubulin, beta 2b Tubb2 1.27 *
81884348 Leucine aminopeptidase Lap3 1.20 *
81910041 WD repeat-containing protein 1 Wdr1 1.13 *
66793366 Glutamyl-prolyl-tRNA synthetase Eprs 1.13 *
47115521 COP9 constitutive photomorphogenic homolog subunit 2 Caps2 1.13 *
300798020 CDGSH iron sulfer domain-containing protein 2 Cisd2 1.10 *
109500010 Similar to H2A histone family, member V isoform 1 LOC685909 1.10 *
61098195 RAB3A Rab3a 0.88 **
94730428 Synaptotagmin-1 Syt1 0.88 **
82546819 Heterogeneous nuclear ribonucleoprotein F Hnrnpf 0.88 *
55727 Snap91 synaptosomal-associated protein 91 Snap91 0.88 **
157822587 Phosphodiesterase 6B Pde6b 0.86 *
6978966 Erythrocyte protein band 4.1-like 3 Epb14.3 0.86 *
547890 Microtubule-associated protein 2 Map2 0.80 *
195539900 Tubulin, beta 4 Tubb4 0.73 *
6981614 Vesicle-associated membrane protein 2 Vamp2 0.71 *
83305012 Neurofilament heavy polypeptiden Nfh 0.68 *
58865424 ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d1 Atp6v0d1 0.63 *
56054 Dynamin 1 Dnm 0.60 *
158635952 Rod-type transducin alpha subunit Gnat1 0.52 *
8394171 Reticulocalbin 2 Rcn 0.06 *
Twenty-seven proteins with significant differences (t-test, *p,0.05, **p,0.01) between diabetic and control groups were identified in the LC-MS/MS analysis.
doi:10.1371/journal.pone.0016271.t004
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monitoring and evaluation of novel treatment efficacy, similar to
previously reported mRNA biomarkers [12]. Further validation is
required before these proteins can be used as surrogate endpoints
in drug testing programs [12]. Additionally, those proteins not
fully normalized by chronic insulin treatment in this study (Fgf2,
Cp, Lgals3, Stat3, Cryba3, Crybb2) may be useful in testing novel
therapeutics intended to be used in conjunction with insulin
therapy to treat those dysregulations caused by diabetes that are
not normalized by insulin replenishment.
Biological functions of confirmed proteins
In agreement with previous reports, diabetes induced retinal
expression of multiple crystallin isoforms was observed. Crystallin
isoforms Cryaa (a-crystallin A), Crybb2 (b-crystallin B2), Cryab (a-
crystallin B) and Cryba3 (b-crystallin A3) were confirmed to be
induced after 3 months of diabetes. Interestingly, Cryba3 protein
expression was only partially normalized by insulin treatment and
Crybb2 protein expression was unaffected.
Crystallin proteins are associated with a variety of functions
ranging from lens structure to stress response, but little is known
about their potential involvement in diabetic retinopathy. Alpha
crystallins, which are similar to small heat shock proteins, have been
reported to have neuroprotective effects [31]. Cryab is upregulated
in activated astrocytes following ischemic damage [32] and
decreases peroxide-induced apoptosis of astrocytes through sup-
pression of caspase-3 signaling [33]. The upregulation of Cryaa and
Cryab with diabetes in our work suggests a potential compensatory
response in the neural retina that may act to protect neurons and
glia from inflammatory insults. Beta crystallins are expressed more
highly in the retina than in other non-lens tissues [34,35], and
Cryba3 was recently reported to be restricted to astrocytes in the
neural retina [36] Neuroprotection of retinal ganglion cells in a
rodent model of ocular hypertension has also been reported to
depend on upregulation of Crybb2. Altered expression of crystallin
proteins has been previously reported with diabetes, although this is
the first study with targeted confirmation analysis of multiple
crystallin isoforms. The findings of this work and other literature
[23,37] suggest a protective role of crystallin upregulation in the
retina with diabetes. The continued induction of Cryba3 and
Crybb2 after restoration of normoglycemia by insulin may be
beneficial but also suggests continuing stress to the retina.
Dbi (diazepam binding inhibitor) and Anxa5 (Annexin A5) were
identified as targets of interest in our iTRAQ analysis. Dbi is an
insulin-regulated transport molecule with numerous functions and
protein interactions ranging from regulation of lipid metabolism
[38] to binding components of inhibitory neurotransmission
machinery [39]. In the retina, Dbi is expressed by pigment
epithelium cells and Mu ¨ller glia [40], and secrete this protein in
response to protein kinase C activation [41]. Dbi binds GABA(A)
receptors with high affinity [42,43], and it is thought that
suppression of GABAergic signaling is one mechanism through
Figure 3. Examples of a differentially-expressed protein identified by iTRAQ. Retinal protein isolated from four diabetic and four age-
matched control rats was labeled with isobaric tags prior to separation, identification, and quantitation by 8-plex iTRAQ using LC/MS/MS. An example
MS/MS spectrum and the corresponding quantitation data (magnification of iTRAQ signal region) for a confidently identified (.95%) peptide
component of Anxa5 are depicted. The signal intensities of all confidently identified peptides unique to Anxa5 were compiled to quantify Anxa5
expression. Anxa5 was significantly increased by approximately two-fold in three-month diabetic rats compared to controls. * p,0.05, two-tailed t-
test, n=4/group.
doi:10.1371/journal.pone.0016271.g003
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inner plexiform layer [40,41,44], which further increases following
activity-dependent phosphorylation [45], which is a hallmark of
diabetes-related retinal pathology [46]. Combined with previous
reports of insulin-mediated regulation of Dbi expression [47,48],
the responsiveness of Dbi protein and mRNA to insulin therapy in
the present study suggests that this target may be a promising
candidate for treatments focused on modulating neurovascular
function in the diabetic retina.
Although well-characterized for its utility as a marker of early
apoptosis due to its high binding affinity for phosphatidylserine,
Anxa5 mediates a variety of cellular functions including adhesion
Figure 4. Coverage and differential expression across analysis methods. Bioinformatic comparison of datasets generated by the three
proteomic and one transcriptomic approaches used was performed to compare commonalities and differences in coverage and differential
expression. (A) Comparison of proteomic coverage of unique species identified across methods is illustrated by Venn diagram. iTRAQ, DIGE and
Luminex provided complementary coverage with limited overlap between methods. Of the 527 unique proteins identified in this study, 110 were
identified by both iTRAQ and DIGE, and only one protein included in the directed Luminex analysis was also identified by an open-profiling method.
For the majority of identified proteins, corresponding transcripts were present at detectable level in the transcriptomic analysis. The greater coverage
of the transcriptomic data compared to the proteomic coverage is primarily due to the greater sensitivity of the whole-genome microarray approach.
(B) Comparison of differentially expressed species detected by each method is depicted. As with proteomic coverage, quantitative data proved
complementary across methods, with a different subset of differentially expressed proteins detected by each of the three proteomic approaches. In
the two cases where a protein was differentially-expressed in both iTRAQ and DIGE quantitation, the direction and magnitude of change were
comparable. Numerous differentially-expressed transcripts were identified by microarray analysis, although only a portion of the proteomic changes
were detected at the transcript level.
doi:10.1371/journal.pone.0016271.g004
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inflammation and apoptosis. This glycoprotein is expressed in
vascular cells [49], neurons [50] and in the blood [51] among
other locations. In the retina, Anxa5 has been localized to the
ganglion cell layer [52], where it may influence neuronal function
through binding of the postsynaptic scaffolding plasma membrane
protein PSD95 [53].
Our data agree with a previous report of upregulated Fgf2
protein levels after 3 months of diabetes in the Sprague Dawley rat
[54]. A novel finding here was that 1.5 months of insulin treatment
did not restore Fgf2 protein or mRNA expression to control levels.
Previously a sustained induction of Fgf2 mRNA levels in spite of
insulin treatment at a one month time point has been reported
[55]. Increased retinal Fgf2 protein levels may serve a neuropro-
tective role [56] and as such, continued induction after insulin
therapy may not be deleterious. However, as Fgf2 is induced by a
wide range of retinal insults, Fgf2 induction may indicate
continued damage to the retina even after restoration of
normoglycemia.
Stat3 activation by diabetes and subsequent blood retinal
barrier damage can be prevented by simvastatin treatment [57].
The angiotensin converting enzyme inhibitor enalapril has been
demonstrated to prevent the diabetes-induced up-regulation of
Stat3 protein [58]. Stat3 can exert a large number of effects as a
signaling regulator to a number of downstream endpoints. As
such, modulation of Stat3 expression likely impacts a variety of
pathways and processes in the retina and may prove to be a useful
target in drug development efforts for diabetic retinopathy.
Figure 5. Confirmation of discovery findings in independent animal sets. Targets identified in the proteomic and transcriptomic analyses
were confirmed at the level of protein expression by immunoblotting in two independent animal sets (Experiments 3 & 4). mRNA expression was also
examined in samples from Experiment 3 by qPCR. Elevated levels of retinal Ceruloplasmin (Cp), Galectin 3 (Lgals3), fibroblast growth factor 2 (Fgf2),
and signal transducer and activator of transcription 3 (Stat3) protein were confirmed in both sets of animals. For these proteins the increase in protein
expression was mirrored by increased mRNA expression. C=Control, D=Diabetic, * p,0.05, ** p,0.01, *** p,0.001, two-tailed t-test.
doi:10.1371/journal.pone.0016271.g005
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16271Lgals3 (lectin, galactoside-binding, soluble 3; galectin-3) is an
abundant protein expressed in the nucleus, cytoplasm, mitochon-
dria, and plasma membrane of multiple cell types including
inflammatory macrophages [59], retinal Mu ¨ller glia [30] and
endothelial cells [60]. This protein binds advanced glycation end
products (AGEs) with high affinity [61] and, as such, may play an
important role in the development of diabetes complications.
Lgals3 expression has previously been reported to increase in
Muller cells of diabetic rats in association with increased acute
phase genes [30]. Lgals3 has also been shown to suppress retinal
angiogenesis [62] and promote inner blood-retina barrier
dysfunction and breakdown [63]. It is likely that increased Lgals3
expression with diabetes is mediated by increased AGE formation
[64,65] and contributes to inflammatory [66] and vascular
components of retinal complications.
Likewise, ceruloplasmin (Cp), an iron binding and metabolizing
a2 globulin, was upregulated with diabetes in this work. This
protein is a component of the acute phase response, and is induced
by inflammation [67,68] as well as interleukin-1 stimulation [69],
although Cp upregulation appears to constitute an anti-inflam-
matory cytoprotective response [67]. Cp protein is increased in
sera from hyperglycemic patients [70] and after optic nerve crush
[71]. Cp transcript is also increased in retinal Mu ¨ller cells of
diabetic rats [30] which may secrete this protein and ultimately
impact retinal microvasculature. It has been proposed that
upregulation of Cp protects against oxidative damage by
decreasing ferritin levels and reducing AGE-mediated damage
[72]. Given the potential protective roles of these proteins, further
study is required before a definitive determination of the benefits
of normalizing their expression with insulin can be made.
Previously, in focused studies examining specific proteins
changes in expression of para-inflammatory and microvascular-
related proteins (e.g., Vegf, Icam1, TNFa, and IL-1b) have been
reported in rodent models of DR. Some of these proteins, such as
Icam1, were not observed with any of the three proteomic
methods used in this study. For other proteins, no changes in
expression were observed (e.g., Vegf, TNFa, and IL-1b). Increased
Vegf protein expression has been reported in the Sprague Dawley
STZ model at after 1 and 6 months of diabetes [73,74] but not
after 3 months [54]. Similarly varying results have been reported
for the induction of both Il-1b and TNFa depending on the
duration of diabetes [54,75–77]. Clearly, there are important
temporal characteristics to the expression of these proteins with
diabetes. The DR field would greatly benefit from a thorough
characterization of the expression and localization of these
proteins across different durations and in multiple rodent models
of diabetes, expanding on work previously reported by Kirwin and
colleagues [54].
Comparison of proteomic technologies
The overarching finding from the comparison of the methods
used in this study is that the different techniques implemented are
complementary rather than redundant. Comparison of the
biophysical properties of proteins identified by the different
methods demonstrated no preferential discrimination of protein
molecular weights between iTRAQ and DIGE. However, the
distribution of identified iTRAQ proteins was skewed toward
hydrophilic proteins while those identified by the DIGE analysis
were more hydrophobic. Proteins detected by the Luminex
analysis were evenly distributed across molecular weights and
hydropathicity. Since Luminex assays are predesigned to select
specific proteins, the technical capabilities of this assay are highly
Figure 6. Confirmation of discovery findings in independent animal sets. Targets identified in the proteomic and transcriptomic analyses
were confirmed at the level of protein expression by immunoblotting in two independent animal sets (Experiments 3 & 4). mRNA expression was also
examined in samples from Experiment 3 by qPCR. Elevated levels of retinal crystallin, alpha B (Cryab); crystallin, beta A3 (Cryba3), crystallin, betaB 2
(Crybb2), diazepam-binding inhibitor (Dbi), and annexin 5 (Anxa5) protein were confirmed in two independent animal sets. Crystallin, alpha A (Cryaa)
was significantly elevated in one set of animals but did not reach significance in the other. For these six proteins there was no concomitant change in
mRNA expression. C=Control, D=Diabetic, * p,0.05, two-tailed t-test.
doi:10.1371/journal.pone.0016271.g006
Figure 7. Responsiveness of protein expression to insulin
therapy. To examine the effect of insulin treatment on protein and
mRNA expression of targets confirmed in the previous experiments, an
independent animal experiment was performed with the addition of an
insulin-treated diabetic group that received insulin for 1.5 months after
1.5 months of diabetes without insulin therapy. Increased retinal
protein and mRNA expression of Cp, Lgals, Fgf2, and Stat3 was
observed. Partial normalization of protein expression by insulin
treatment was observed for Cp, Lgals3, and Stat3, i.e., expression of
those proteins in the insulin-treated group was not significantly
different compared to either the control or untreated diabetic group.
Fgf2 protein expression remained significantly elevated in the insulin
treated group compared to controls. mRNA expression responsiveness
was more complex with Lgals3 mRNA levels completely normalized, Cp
mRNA levels partially normalized, and Fgf2 and Stat3 levels remaining
elevated. C=Control, D=Diabetic, D+I=Diabetic with insulin, * p,0.05,
** p,0.01, one-way ANOVA, Student Newman Keuls post-hoc test.
doi:10.1371/journal.pone.0016271.g007
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transcriptomic analysis provided novel targets not observed in any
of the proteomic analyses. Interestingly, all targets chosen from the
transcriptomic analysis were confirmed at both the mRNA and
protein levels. In total, the comparison of mRNA and protein
expression levels demonstrates that while mRNA changes are not
determinative of protein expression changes in many cases they
are highly correlated.
This study identified a number of retinal protein expression
changes with diabetes. Of particular interest for future studies are
those proteins that are not normalized (Fgf2 and Crybb2) or only
partially normalized (Cp, Cryba3, Lgals3, Stat3) by insulin
treatment, as these persistent changes reflect the limitations of
insulin to restore the retina to a nondiabetic state. The lack of
complete normalization by insulin treatment offers the potential
that these proteins may play a role in the ‘metabolic memory’ [78]
observed clinically in retinopathy pathogenesis [79]. Future studies
will address when these protein changes first occur as well as the
cellular origin of these proteins and the mechanisms underlying
their continued dysregulation despite insulin replacement.
Materials and Methods
Ethics Statement
All animal experimental procedures were approved by and
carried out in accordance with the Penn State College of Medicine
Institutional Animal Care and Use Committee (Approval ID
Number: 2006–093). Animal surgery and sacrifice was performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering.
Animal Methods
All rats were maintained by the Penn State JDRF Animal
Models Core in accordance with the Penn State College of
Medicine Institutional Animal Care and Use Committee guide-
lines under specific pathogen-free conditions and monitored by
quarterly sentinel testing. Diabetes was induced in male Sprague-
Dawley rats (Charles River Laboratories, Wilmington, MA) (100–
125 g at arrival) by intraperitoneal streptozotocin as previously
described [14]. Control rats were injected with an equal dose of
vehicle. Only STZ-injected rats with blood glucose levels
.250 mg/dL throughout the experiment were included in this
study (Table 1). No exogenous insulin was delivered in animal
experiments 1-4. For animals in experiment 5, the insulin
treatment group received one 26 mg subcutaneous pellet (LinShin
Canada, Scarborough, Canada) delivered via trocar 6 weeks post-
STZ injection. An additional 26 mg implant was introduced when
body weight exceeded 300 g or when midday non-fasting blood
glucose exceeded 250 mg/dL. Blood glucose monitoring, animal
sacrifice, and retina excision were conducted as previously
described [12]. Glycosylated hemoglobin was measured from
drops of blood acquired by nicking the tail, using a Lifescan
glucose meter and Siemens DCA Analyzer, respectively.
DIGE
Quantitative two-dimensional in-gel electrophoresis (DIGE) was
performed as detailed previously [80,81]. All DIGE methods and
results are provided in MIAPE-GE compliant form [82]. Retinas
[control, n=8; diabetic, n=8; (Experiment 1, Table 1)] were
homogenized in lysis buffer, and soluble proteins were purified,
quantitated, and labeled with Cy3 and Cy5 dyes as previously
described [81]. A normalization pool containing equal protein
from each sample, for inclusion on each 2D gel, was labeled with
Cy2. 250 mg of unlabeled protein from a representative pool
containing equal protein from all samples was used for a
preparative/picking gel for mass spectrometry (MS) identification
of protein species. First and second dimension separation was
Figure 8. Responsiveness of protein expression to insulin
therapy. To examine the effect of insulin treatment on protein and
mRNA expression for those targets confirmed in the previous
experiments, an independent animal experiment was performed with
the addition of an insulin-treated diabetic group that received insulin
for 1.5 months after 1.5 months of diabetes without insulin therapy.
Increased retinal protein expression of Cryba3, Crybb2, Dbi, and Anxa5
was again observed. Retinal Dbi protein expression was completely
normalized by insulin treatment, while Cryba3 protein expression was
partially normalized. Crybb2 expression remained elevated following
1.5 months of insulin treatment. The previously observed elevations in
Cryaa and Cryab were not recapitulated in this set of animals.
C=Control, D=Diabetic, D+I=Diabetic with insulin, * p,0.05,
** p,0.01, one-way ANOVA, Student Newman Keuls post-hoc test.
doi:10.1371/journal.pone.0016271.g008
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with a Typhoon 9410 scanner (GE Healthcare) and analyzed
using semi-automated DeCyder 6.5 software (GE Healthcare).
For each protein spot, the ratio of background-subtracted
sample-specific signal (Cy3 or Cy5 density) to normalization pool
signal (Cy2) was calculated. Only protein spots detected on $6/8
analytical gels were included in quantitation analysis. One-way
ANOVA (p,0.05) and a 1.1-fold change cutoff were used to
determine protein spots significantly regulated with diabetes.
MALDI-ToF/ToF Mass Spectrometry
MALDI-ToF/ToF mass spectrometry was performed as
described previously [81,83]. Spots of interest were excised from
the picking gel using a robotic Ettan Spot Picker (GE Healthcare),
and gel plugs were subjected to in-gel trypsin digestion and ZipTip
(Millipore, Bedford, MA) desalting. Protein identifications were
performed by peptide mass fingerprinting (MS and MS/MS) using
standard laboratory methods and a Applied Biosystems 4800
Proteomics Analyzer in reflector positive mode [80,81]. An
exclusion list containing autolytic tryptic peptides, human keratin,
matrix, and precursor peptides identified in a ‘‘blank’’ gel plug was
included as an additional filter. Data interpretation was performed
using GPS explorer (v3.6) and database searching was carried out
using MASCOT (v2.0.00). Database searches were carried out
against the Rattus taxonomy of the NCBI database downloaded on
Feb 16 2008 (107,758 entries searched). In the final combined MS
and MS/MS database searches, identifications required a
MASCOT confidence interval $95%.
iTRAQ analysis
8-Plex iTRAQ (Applied Biosystems) sample preparation and
labeling were performed according to manufacturer’s instructions
as previously described [23] with samples from Experiment 1
(Table 1). Following purification by acetone precipitation, 100 mg
of retinal protein from each of four control and four diabetic rats
was reconstituted in dissolution buffer (0.5 M TEAB, pH 8.5),
denatured with 2%SDS, and alkylated/reduced with 5 mM
TCEP/20 mM MMTS. Trypsin digestion was conducted over-
night at 37uC by incubation with sequencing-grade trypsin prior to
labeling with 8-plex iTRAQ reagents. The eight labeled samples
were combined and prepared in 10 mM KH2PO4 for LC-SCX
separation. SCX separations were performed on a passivated
Waters 600E HPLC system, using a PolySULFOETHYL
Aspartamide column (PolyLC, Columbia, MD) prior to reverse
phase C18 nanoflow-LC separation performed using a Tempo LC
MALDI Spotting System (ABI-MDS/Sciex) and a Chromolith
CapRod column (Merck).
MALDI target plates were analyzed in a data-dependent
manner on an ABI 4800 MALDI TOF-TOF. Both MS and
MS/MS default calibrations were performed using the Applied
Biosystems Calibration Mixture 1. MS Spectra were acquired
from each sample spot and selected peaks were analyzed by MS/
MS with collision-induced decay.
Protein identification and quantitation were performed using
the Paragon algorithm as implemented in Protein Pilot 2.0
software (ABI/MDS-Sciex). Database searches were carried out
against the Rattus subset of the NCBI database downloaded on July
22 2008 (109,096 entries searched) with a concatenated with a
reversed ‘‘decoy’’ version. Confident protein identifications
required a ProteinPilot Unused Score of at least 1.3 (95%
confidence interval) and a Local False Discovery Rate estimation
with a decoy database of no higher than 5% using PSPEP software
[84].
Luminex
Retina protein profiling was performed at Rules-Based
Medicine (Austin, Texas) using standard Luminex technology
[27]. Retinal samples (in triplicate) from Experiment 1 (Table 1)
(n=8/group) were subjected to RodentMap antigen analysis for
59 different circulating proteins. Samples were mixed with capture
microspheres, incubated with multiplexed biotinylated reporter
antibodies, and developed with streptavadin-phycoerythrin. Anal-
ysis was performed in a Luminex 100 instrument, with analytes
quantitated using 4 and 5 parameter, weighted and non-weighted
curve fitting algorithms included in the data analysis package.
RNA Isolation
Retina homogenization and RNA isolation was performed by
standard Tri Reagent/BCP disruption and phase separation
followed by over-night isopropanol precipitation at -20uC, as
previously described [14]. After purification using Qiagen RNeasy
Mini kit (Qiagen), RNA was assessed for quantity and quality
using a NanoDrop ND1000 (Thermo Scientific, Wilmington, DE)
and RNA 6000 Nano LabChip with an Agilent 2100 Expert
Bioanalyzer (Agilent, Palo Alto, CA), respectively.
Microarray analysis
Microarray analysis was performed with Illumina RatRef12
microarrays (Illumina, San Diego, CA) according to standard
procedures [15] using five control and five diabetic rats from
Experiment 2 (Table 1). 500 ng RNA was reverse transcribed to
first strand cDNA by incubation with T7 Oligo(dT) primer, 106
First Strand buffer, dNTPs, Rnase inhibitor, and ArrayScript.
Second strand cDNA was synthesized with 106 second strand
buffer, dNTPs, DNA polymerase and RNase H. Purified cDNA
was eluted in nuclease-free water and in vitro transcribed to
synthesize cRNA by incubation with T7 106Reaction buffer, T7
Enzyme mix and Biotin-NTP mix. cRNA was purified according
to manufacturer’s instructions and quantitated using a NanoDrop
ND1000 spectrometer. 750 ng of purified cRNA was prepared for
hybridization and incubated with RatRef-12 BeadChips prior to
washing and staining with streptavadin-Cy3 stained. BeadChips
were then dried and subsequently scanned using a BeadStation
BeadArray Reader.
After initial quality control of arrays, one array from the
diabetic group was removed. GenomeStudio (Illumina) flat files
were imported into GeneSpring GX11 (Agilent) software for data
analysis. Using the detection p-values initially generated in
GenomeStudio, probes were required to have detectable signal
(marginal or present calls) in all arrays for at least one of the two
groups in the experiment to be included in the subsequent
statistical analyses. This filtering eliminates from further analysis
transcripts not reliably detected, while retaining genes potentially
expressed in only one group (i.e., expressed only in control or only
in diabetic). The full complement of microarray data is available in
the Gene Expression Omnibus [85], accession # GSE20886.
To determine differential expression, a combination of statistical
p value (two-tailed t-test, p,0.05) and fold-change ($1.2 fold)
cutoffs were used in accordance with standards in data analysis
[86] and our previously published methods [14,15]. Differential
mRNA expression data were used to generate a heatmap
representation of retinal transcriptomic profiles. The heatmap
was organized by up- and down-regulated expression segregated
by horizontal brackets. Individual animals were clustered by
Euclidean distance using K-means with complete linkage hierar-
chy (vertical brackets).
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Quantitative PCR confirmations were performed as described
previously [12,14] using an 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA), 384-well optical plates, and
Assay-On-Demand (Applied Biosystems) gene specific primers and
probes (Experiments 3 and 5, n=8–9/group, Table 1). SDS 2.2.2
software and the 2
2DDCt analysis method were used to quantitate
relative amounts of product using b-actin as an endogenous
control [12]. b-actin levels were determined to be unchanged in an
absolute quantitation experiment (data not shown). For a full
listing of primer/probe sets see Table S5.
Immunoblot analysis
Soluble retinal protein was isolated from independent sets of
animals (Experiments 3–5, n=8–10/group, Table 1) by homog-
enization in 250 mL detergent-based protein lysis buffer (2.5 mM
HEPES, 1 mM EDTA, 100 mM NaCl, 1 mM dithiothreitol, 1%
Tween 20, 1 mM Na3VO4, 2 protease inhibitor tablets/15 mL).
Insoluble material was removed by centrifugation at 10,0006g for
10 minutes at 4uC. Protein concentrations were determined by
Pierce BCA reagent. Samples were separated on Criterion 4–20%
gradient gels (Bio-Rad) and transferred to either PVDF or LF-
PVDF membranes (GE Healthcare) depending on the manner of
subsequent visualization (chemiluminescence or fluorescence).
Membranes were incubated with primary and secondary antibod-
ies as described in Table S6. Images were analyzed with
ImageQuant TL (GE Healthcare).
Statistical Analysis
For all immunoblot and qPCR experiments, the data for
individual samples were normalized to the respective actin signal.
Statistical analyses were conducted using SigmaStat 3.5 software,
with two-tailed t-tests for two group comparisons (control vs.
diabetic) and one-way ANOVA with pair-wise Student Newman
Keuls post-hoc tests for multiple group comparisons.
Bioinformatic Analysis
Coverage and differential expression between proteomic and
transcriptomic approaches were evaluated. Protein accession
numbers and gene IDs were converted to gene symbols using
Ingenuity Pathway Analysis (IPA) software to eliminate potential
redundancy and incomplete mapping of identifiers. Proteins with
multiple identifications in a method (e.g., multiple spots with the
same protein ID in the DIGE experiment) were compressed to one
unique gene symbol. Overlap between Luminex, DIGE, and
iTRAQ coverage (i.e., unique detected/identified proteins) was
visualized by Venn diagram. Total proteomic coverage (i.e., the
union of the three proteomic approaches) was then compared to
transcriptomic coverage. Similarly, Venn diagrams were created
to illustrate commonalities and differences in differentially
regulated species detected by proteomic and transcriptomic
methods.
The biophysical properties of detected/identified proteins for
each proteomic method (Luminex, DIGE, iTRAQ) were deter-
mined. NCBI gi| accession numbers were translated to UniProt/
Swiss-Prot accession numbers and imported into the Swiss
Institute of Bioinformatics Expert Protein Analysis System
(ExPASy) ProtParam tool (http://www.expasy.org). Molecular
weights and grand average of hydropathicity (GRAVY) scores
were retrieved for each unique protein, and binned according to
size (0 kDa to .150 kDa) and score (,21.0 to .0.4) for
comparison of frequency distributions.
Supporting Information
Figure S1 Whole-genome gene expression analysis.
Retinal RNA from control (n=5) and diabetic (n=4) rats
collected after 3 months of hyperglycemia was analyzed by
Illumina Rat Ref12 microarray. 11,874 of 22,517 probes on the
microarray had detectable signals. The 1,274 probes with
significantly different expression between control and diabetic
groups (two-tailed t-test, p,0.05, 1.2 fold cut-off), including 583
down-regulated and 691 up-regulated genes, are shown.
(TIF)
Figure S2 Comparison of biophysical properties of
identified proteins. The biochemical characteristics of proteins
identified by the three complementary proteomic methods are
illustrated by frequency plots. (A) Molecular weight distributions of
unique species identified in iTRAQ, DIGE and Luminex
approaches are depicted as the percent of the total protein
coverage for each method. Proteins identified in iTRAQ and
DIGE were similarly distributed across a broad molecular weight
range, while the directed Luminex approach provided better
coverage of smaller (10–30 kDa) species. (B) The relative
hydrophobicity/hydrophilicity of proteins identified by the three
approaches were compared using grand average of hydropathicity
(GRAVY) scores for each protein. All three methods provided
broad coverage ranging from hydrophilic (negative score) to
hydrophobic (positive score) proteins. A greater percentage of the
proteins observed in the iTRAQ analysis were hydrophilic in
nature while DIGE or Luminex approaches had a greater
percentage of hydrophobic proteins, further demonstrating the
complementarity of the three approaches.
(TIF)
Table S1 Primary data from Luminex analysis
(XLS)
Table S2 Primary data from DIGE analysis
(XLS)
Table S3 Primary data from iTRAQ analysis
(XLS)
Table S4 Differentially expressed genes from transcrip-
tomic analysis
(XLS)
Table S5 Primer/probe sets used in qPCR confirma-
tions
(DOC)
Table S6 Antibodies used in immunoblot confirmations
(DOC)
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